Favorable initial results from a phase 1/2 trial of solnerstotug in PD-L1–resistant tumors showed a 14% response rate and 62% ...

The Business Research Company Updated 2025 Market Reports have released and offer essential trends and forecasts up to 2034. Early purchase is your competitive edge! LONDON, GREATER LONDON, UNITED KIN ...

Libtayo, a monoclonal antibody, works by targeting the immune receptor PD-1 on T cells, helping to prevent cancer cells from immune system attacks. In addition to now being approved for NSCLC and BCC, ...

Immuneering has reached out to Regeneron to lend its monoclonal antibody Libtayo to use it in combination with IMM-1-104 in a phase 2 trial. The terms of the deal were not disclosed. Immuneering will ...

Their new study, published in Science Translational Medicine, identifies powerful antibodies capable of neutralizing a wide range of norovirus strains. The finding could lead to the design of broadly ...

A team has found two antibodies that can work together to neutralize the virus that causes COVID-19 in all its current known variations in a laboratory environment. More research is needed ...

In a small study in a community oncology practice, more than 60% of patients with advanced squamous cell skin cancer treated with Libtayo achieved complete remission. An immunotherapy produced ...

James Harrison earned the nickname “The Man With the Golden Arm” because his blood had a rare antibody that may have helped more than two million babies in Australia. By Amelia Nierenberg ...

The THIO-101 study in 3L will enroll up to 48 patients with two arms: Arm 1, continuing the evaluation of THIO sequenced with Libtayo ® (cemiplimab); and Arm 2, evaluating THIO as a monotherapy ...

The THIO-101 study in 3L will enroll up to 48 patients with two arms: Arm 1, continuing the evaluation of THIO sequenced with Libtayo ® (cemiplimab); and Arm 2, evaluating THIO as a monotherapy, to ...